Its name — “delta sleep-inducing peptide” — is a promise the evidence doesn’t really keep. Here’s what DSIP is, what the research honestly shows, its 2026 US regulatory status, and why the sleep basics beat it.
The headline, up front: despite being literally named “delta sleep-inducing peptide,” DSIP has never been shown to reliably induce or improve sleep in humans. The studies are old, small, and inconsistent, and it never became an established sleep treatment. If you’re buying it as a sleep aid, the name is doing more work than the evidence.
DSIP (delta sleep-inducing peptide) is a naturally occurring nine-amino-acid peptide first identified decades ago in sleep research — which is where the name comes from. It’s also referred to as emideltide. Beyond the sleep association, it has been studied for possible effects on stress hormones, pain, and stress resilience, but its mechanism is poorly understood and none of these uses is well established. It’s best thought of as an under-characterized peptide with an evocative name.
Here’s the honest core: the research on DSIP for sleep is sparse, dated, and mixed. Some early work suggested effects on sleep or stress measures; other studies didn’t replicate a clear sleep benefit. Crucially, in the decades since its discovery, DSIP never translated into an established or approved sleep therapy — which is itself telling. For the thing people most want it for, the evidence does not clearly deliver.
Limited — other uses (stress, pain) are exploratory at bestThe non-sleep uses are even less established — interesting in research terms, not demonstrated as real-world benefits.
If sleep is the actual goal, the unglamorous fundamentals have far stronger evidence than DSIP:
Spending on an unproven peptide while a treatable sleep disorder goes unaddressed is the real downside here — the opportunity cost, not just the money.
DSIP is not FDA-approved. As emideltide, it was removed from the FDA’s Category 2 list in April 2026 and is one of the seven peptides on the July 23–24, 2026 PCAC docket for the 503A compounding list — so its status could change. See our research peptide legal status guide for the current picture.
DSIP is a genuine research peptide with an unusually persuasive name and an unusually thin track record for the use that name implies. It hasn’t been shown to reliably improve human sleep, its mechanism is murky, and the safety/dosing picture is limited. If sleep is the problem, the evidence-based basics and a clinician will do far more than DSIP — treat it as an interesting molecule, not a sleep solution.
The evidence is weak and inconsistent — despite the name. It was found in sleep research but never became an established sleep treatment, and studies are old, small, and mixed.
A naturally occurring nine-amino-acid peptide (also called emideltide), studied for sleep, stress hormones, and pain — but poorly understood, with no well-established function.
Not FDA-approved; sold “research use only.” Removed from Category 2 in April 2026 and on the July 2026 PCAC docket (as emideltide) — see the legal-status guide.
Mainly the expectation gap (unproven for sleep) plus limited safety data, little dosing guidance, and unverified gray-market purity.
For most people, sleep fundamentals and treating underlying issues with a clinician have far stronger evidence than DSIP.
This guide is general legal and educational information, not legal or medical advice, and does not create an attorney-client or physician-patient relationship. It is written by a California-licensed attorney, not a physician. DSIP is not FDA-approved and is not an established treatment for sleep or any other condition; persistent sleep problems should be evaluated by a licensed clinician. Research peptides sold “for research use only” are not approved for human use. Verify current information before relying on it. Current as of June 20, 2026.